Marshall Wace LLP Acquires 48,930 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Marshall Wace LLP raised its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 41.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 166,425 shares of the company’s stock after acquiring an additional 48,930 shares during the period. Marshall Wace LLP owned about 0.32% of Kodiak Sciences worth $391,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of KOD. Headlands Technologies LLC bought a new position in shares of Kodiak Sciences in the 1st quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences in the first quarter valued at about $68,000. Meeder Asset Management Inc. acquired a new stake in shares of Kodiak Sciences during the second quarter valued at about $36,000. Diversified Trust Co bought a new stake in shares of Kodiak Sciences during the first quarter worth about $83,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Kodiak Sciences in the first quarter valued at approximately $86,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Trading Up 2.7 %

Shares of KOD stock opened at $2.69 on Friday. The stock has a 50-day moving average of $2.58 and a 200-day moving average of $3.10. The stock has a market cap of $141.32 million, a price-to-earnings ratio of -0.61 and a beta of 2.34. Kodiak Sciences Inc. has a 1-year low of $1.37 and a 1-year high of $7.77.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.01. Sell-side analysts forecast that Kodiak Sciences Inc. will post -3.52 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.00.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.